Invesco Ltd. Chinook Therapeutics, Inc. Transaction History

Invesco Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $25,526 - $52,777	1,368 Added 3.62%	39,106 $1.5 Million
Q1 2023 May 12, 2023	SELL	$21.53 - $26.8 $3.68 Million - $4.58 Million	-170,794 Reduced 81.9%	37,738 $873,000
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $250,051 - $367,091	13,422 Added 6.88%	208,532 $5.46 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $2.65 Million - $3.54 Million	-151,544 Reduced 43.72%	195,110 $3.84 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $3.98 Million - $5.94 Million	315,755 Added 1021.89%	346,654 $6.06 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $238,621 - $331,329	19,852 Added 179.7%	30,899 $506,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $10,102 - $15,904	-945 Reduced 7.88%	11,047 $180,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $17,388 - $22,468	1,512 Added 14.43%	11,992 $153,000
Q2 2021 Aug 17, 2021	BUY	$13.6 - $18.98 $142,528 - $198,910	10,480 New	10,480 $148,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.